ARNI treatment in HFpEF shows benefit in secondary outcomes, but misses significance in primary endpoint - PACE-CME

ARNI treatment in HFpEF shows benefit in secondary outcomes but misses significance in primary endpoint

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Biochemical urine test to measure medical adherence in hypertension
Biochemical urine test to measure medical adherence in hypertension
ESC 2019
Biochemical urine test to measure medical adherence in hypertension
Hs-troponin measured 30 min after admission to diagnose MI
Hs-troponin measured 30 min after admission to diagnose MI
ESC 2019
Hs-troponin measured 30 min after admission to diagnose MI
- Camilla Bang, MD
What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?
What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?
ESC 2019
What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?
- Prof. François Mach, MD
NP metabolism associated with clinical outcomes in HF
NP metabolism associated with clinical outcomes in HF
ESC 2019
NP metabolism associated with clinical outcomes in HF
- Frank Gommans, MD, PhD